Taken together, the combination of bortezomib and venetoclax targets the pro-survival function of LMP-1 and EBNA-3C of Epstein-Barr virus in post-transplant lymphoproliferative disorder. The gene discussed is PDLIM7; the disease is lymphoproliferative syndrome.